Drug Profile
Cancer vaccine - Sanofi
Alternative Names: Breast cancer vaccine - Sanofi ; Ovarian cancer vaccine - SanofiLatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Malignant melanoma; Renal cancer
Most Recent Events
- 06 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the adverse events and Cancer therapeutic trials sections
- 06 Jul 2004 Genzyme has completed enrolment in a phase I/II (electrofusion) trial for renal cancer in the USA
- 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation